Literature DB >> 15633995

Control of hepatitis C: a medicinal chemistry perspective.

Christopher P Gordon1, Paul A Keller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15633995     DOI： 10.1021/jm0400101

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  17 in total

1.  Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor.

Authors:  Anita Y M Howe; Huiming Cheng; Ian Thompson; Srinivas K Chunduru; Steve Herrmann; John O'Connell; Atul Agarwal; Rajiv Chopra; Alfred M Del Vecchio
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 2.  Advances in nucleoside monophosphate prodrugs as anti-HCV agents.

Authors:  Drew R Bobeck; Raymond F Schinazi; Steven J Coats
Journal:  Antivir Ther       Date:  2010

3.  Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor.

Authors:  Steven Harper; John A McCauley; Michael T Rudd; Marco Ferrara; Marcello DiFilippo; Benedetta Crescenzi; Uwe Koch; Alessia Petrocchi; M Katharine Holloway; John W Butcher; Joseph J Romano; Kimberly J Bush; Kevin F Gilbert; Charles J McIntyre; Kevin T Nguyen; Emanuela Nizi; Steven S Carroll; Steven W Ludmerer; Christine Burlein; Jillian M DiMuzio; Donald J Graham; Carolyn M McHale; Mark W Stahlhut; David B Olsen; Edith Monteagudo; Simona Cianetti; Claudio Giuliano; Vincenzo Pucci; Nicole Trainor; Christine M Fandozzi; Michael Rowley; Paul J Coleman; Joseph P Vacca; Vincenzo Summa; Nigel J Liverton
Journal:  ACS Med Chem Lett       Date:  2012-03-02       Impact factor: 4.345

4.  Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure.

Authors:  Michael T Rudd; John A McCauley; John W Butcher; Joseph J Romano; Charles J McIntyre; Kevin T Nguyen; Kevin F Gilbert; Kimberly J Bush; M Katharine Holloway; John Swestock; Bang-Lin Wan; Steven S Carroll; Jillian M DiMuzio; Donald J Graham; Steven W Ludmerer; Mark W Stahlhut; Christine M Fandozzi; Nicole Trainor; David B Olsen; Joseph P Vacca; Nigel J Liverton
Journal:  ACS Med Chem Lett       Date:  2011-01-12       Impact factor: 4.345

5.  Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection.

Authors:  Netanya G Sandler; Christopher Koh; Annelys Roque; Jason L Eccleston; Rebecca B Siegel; Mary Demino; David E Kleiner; Steven G Deeks; T Jake Liang; Theo Heller; Daniel C Douek
Journal:  Gastroenterology       Date:  2011-07-02       Impact factor: 22.682

6.  In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.

Authors:  Tse-I Lin; Oliver Lenz; Gregory Fanning; Thierry Verbinnen; Frédéric Delouvroy; Annick Scholliers; Katrien Vermeiren; Asa Rosenquist; Michael Edlund; Bertil Samuelsson; Lotta Vrang; Herman de Kock; Piet Wigerinck; Pierre Raboisson; Kenneth Simmen
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

7.  Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro.

Authors:  Hyo-Joong Kim; Ashoke Sharon; Chandralata Bal; Jianing Wang; Madhan Allu; Zhuhui Huang; Michael G Murray; Leda Bassit; Raymond F Schinazi; Brent Korba; Chung K Chu
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

Review 8.  Sex, sex steroids, and brain injury.

Authors:  Paco S Herson; Ines P Koerner; Patricia D Hurn
Journal:  Semin Reprod Med       Date:  2009-04-28       Impact factor: 1.303

9.  NS3 Peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: its mechanism of action and antiviral activity in the replicon system.

Authors:  Agnieszka Gozdek; Igor Zhukov; Agnieszka Polkowska; Jaroslaw Poznanski; Anna Stankiewicz-Drogon; Jerzy M Pawlowicz; Wlodzimierz Zagórski-Ostoja; Peter Borowski; Anna M Boguszewska-Chachulska
Journal:  Antimicrob Agents Chemother       Date:  2007-11-26       Impact factor: 5.191

10.  HCV genetics and genotypes dictate future antiviral strategies.

Authors:  Louis Papageorgiou; Chrisanthy Vlachakis; Konstantina Dragoumani; Sofia Raftopoulou; Dimitrios Brouzas; Nicolas C Nicolaides; George P Chrousos; Evangelia Charmandari; Vasileios Megalooikonomou; Dimitrios Vlachakis
Journal:  J Mol Biochem       Date:  2017-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.